For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 131,980 | |||
| Research and development related success payments and contingent consideration | 29,432 | |||
| General and administrative | 44,296 | |||
| Impairment of long-lived assets | 44,611 | |||
| Total operating expenses | 250,319 | |||
| Loss from operations | -250,319 | |||
| Interest income, net | 3,848 | |||
| Other income (expense), net | 2,305 | |||
| Net loss | -244,166 | |||
| Basic EPS | -0.96 | |||
| Diluted EPS | -0.96 | |||
| Basic Average Shares | 253,234,000 | |||
| Diluted Average Shares | 253,234,000 | |||
Sana Biotechnology, Inc. (SANA)
Sana Biotechnology, Inc. (SANA)